Xalkori crizotinib: Phase I data

Data from an expansion cohort of 13 advanced NSCLC patients with a c-ros oncogene 1 ( ROS1) rearrangement, 12 of whom were ALK-negative, in a Phase I trial showed that twice-daily 250 mg oral Xalkori led to an ORR of 54%, including 1 complete response and 6 partial responses. The DCR at 8 weeks was 85%. Pfizer said the data show that like ALK, ROS1 defines a distinct subpopulation of NSCLC patients for whom Xalkori may be highly effective. Data were presented at the American Society of Clinical Oncology meeting in Chicago. ...